{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:40:47Z","timestamp":1762004447385,"version":"build-2065373602"},"reference-count":33,"publisher":"BMJ","issue":"2","funder":[{"name":"AbbVie"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,12,7]]},"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The current American College of Rheumatology and European League Against Rheumatism treatment recommendations advise tapering biological disease-modifying antirheumatic drug (bDMARD) therapy in patients with rheumatoid arthritis (RA) who achieve stable clinical remission while receiving bDMARDs. However, not all patients maintain remission or low disease activity after tapering or discontinuation of bDMARDs. The aim of the Im<jats:italic>P<\/jats:italic>act of<jats:italic>R<\/jats:italic>esidual Inflammation Detected via Imaging T<jats:italic>E<\/jats:italic>chniques,<jats:italic>D<\/jats:italic>rug Levels and Patient Characteristics on the Outcome of Dose Taper<jats:italic>I<\/jats:italic>ng of Adalimumab in<jats:italic>C<\/jats:italic>linical Remission Rheumatoid Ar<jats:italic>T<\/jats:italic>hritis (<jats:italic>RA<\/jats:italic>) study, or PREDICTRA, is to generate data on patient and disease characteristics that may predict the clinical course of a fixed dose-tapering regimen with the bDMARD adalimumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>PREDICTRA is an ongoing, multicentre, phase IV, randomised, double-blind, parallel-group study of adalimumab dose tapering controlled by withdrawal in participants with RA who achieved stable clinical remission while receiving adalimumab. The study includes a screening period, a 4-week lead-in period with open-label adalimumab 40\u2009mg every other week and a subsequent 36-week double-blind period during which participants are randomised 5:1 to adalimumab 40\u2009mg every 3 weeks (taper arm) or placebo (withdrawal arm). The primary explanatory efficacy variables are lead-in baseline hand and wrist MRI-detected synovitis and bone marrow oedema scores, as well as a composite of both scores; the dependent variable is the occurrence of flare up to week 40. Additional efficacy variables, safety, pharmacokinetics, biomarkers and immunogenicity will also be assessed, and an ultrasound substudy will be conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The study is conducted in accordance with the International Conference on Harmonisation guidelines, local laws and the ethical principles of the Declaration of Helsinki. All participants are required to sign a written informed consent statement before the start of any study procedures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>EudraCT 2014-001114-26 and<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT02198651\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\">NCT02198651<\/jats:ext-link>; Pre-results.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2017-019007","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T13:15:42Z","timestamp":1519823742000},"page":"e019007","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im<i>P<\/i>act of<i>R<\/i>esidual Inflammation Detected via Imaging T<i>E<\/i>chniques,<i>D<\/i>rug Levels and Patient Characteristics on the Outcome of Dose Taper<i>I<\/i>ng of Adalimumab in<i>C<\/i>linical Remission Rheumatoid Ar<i>T<\/i>hritis (<i>RA<\/i>) patients (PREDICTRA)"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02198651","registry":"10.18810\/clinical-trials-gov","type":"preResults"},{"clinical-trial-number":"nct02198651","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02198651","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Paul","family":"Emery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Naredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Hojnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip G","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,2,28]]},"reference":[{"key":"2024051710343737000_8.2.e019007.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24724"},{"key":"2024051710343737000_8.2.e019007.2","first-page":"S295","article-title":"Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis","volume":"18","author":"Gibofsky","year":"2012","journal-title":"Am J Manag Care"},{"key":"2024051710343737000_8.2.e019007.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.1.28"},{"key":"2024051710343737000_8.2.e019007.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"2024051710343737000_8.2.e019007.5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030275","article-title":"Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis","volume":"7","author":"Aaltonen","year":"2012","journal-title":"PLoS One"},{"key":"2024051710343737000_8.2.e019007.6","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta10420","article-title":"A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness","volume":"10","author":"Chen","year":"2006","journal-title":"Health Technol Assess"},{"key":"2024051710343737000_8.2.e019007.7","unstructured":"Humira (adalimumab). Full prescribing information. North Chicago, IL: AbbVie Inc, 2016."},{"key":"2024051710343737000_8.2.e019007.8","unstructured":"Humira Summary of Product Characteristics. 2016. http:\/\/www.ema.europa.eu (accessed 19 Apr 2016)."},{"key":"2024051710343737000_8.2.e019007.9","first-page":"1","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"2016","author":"Singh","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024051710343737000_8.2.e019007.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"2024051710343737000_8.2.e019007.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61751-1"},{"key":"2024051710343737000_8.2.e019007.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316133"},{"key":"2024051710343737000_8.2.e019007.13","first-page":"S19","article-title":"The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials","volume":"31","author":"Kavanaugh","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2024051710343737000_8.2.e019007.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205726"},{"key":"2024051710343737000_8.2.e019007.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61811-X"},{"key":"2024051710343737000_8.2.e019007.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206696"},{"key":"2024051710343737000_8.2.e019007.17","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22303"},{"key":"2024051710343737000_8.2.e019007.18","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0927-z"},{"key":"2024051710343737000_8.2.e019007.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev006"},{"key":"2024051710343737000_8.2.e019007.20","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/rheumatology\/kex184","article-title":"Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors","volume":"56","author":"Lamers-Karnebeek","year":"2017","journal-title":"Rheumatology"},{"key":"2024051710343737000_8.2.e019007.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.23945"},{"key":"2024051710343737000_8.2.e019007.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.125534"},{"key":"2024051710343737000_8.2.e019007.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204632"},{"key":"2024051710343737000_8.2.e019007.24","first-page":"S22","article-title":"Discontinuation of biologics in patients with rheumatoid arthritis","volume":"31","author":"Tanaka","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2024051710343737000_8.2.e019007.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.121491"},{"key":"2024051710343737000_8.2.e019007.26","doi-asserted-by":"crossref","first-page":"A208.3","DOI":"10.1136\/annrheumdis-2013-eular.664","article-title":"THU0136\u2005long term outcomes of stopping tumour necrosis factor inhibitors (tnfi) in patients with established rheumatoid arthritis (RA) Who are in sustained remission: is it worth the risk?","volume":"72","author":"Rakieh","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2024051710343737000_8.2.e019007.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2024051710343737000_8.2.e019007.28","first-page":"S93","article-title":"The disease activity score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2024051710343737000_8.2.e019007.29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084459"},{"key":"2024051710343737000_8.2.e019007.30","doi-asserted-by":"publisher","DOI":"10.1186\/ar4035"},{"key":"2024051710343737000_8.2.e019007.31","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2013-132121"},{"key":"2024051710343737000_8.2.e019007.32","first-page":"S-17","article-title":"Optimal use of MRI in clinical trials, clinical care and clinical registries of patients with rheumatoid arthritis","volume":"32","author":"\u00d8stergaard","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2024051710343737000_8.2.e019007.33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000225"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-019007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:03:03Z","timestamp":1715972583000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-019007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,28]]},"published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1136\/bmjopen-2017-019007"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-019007","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}